M&A / Deals Merck’s deal for Terns sparks debate over a possible biotech bidding war BioPharma DiveSome investors and analysts believe the pharma s $6.7 billion offer is justified given Terns recent stock run.M&A / DealsRead full story pharminent March 26, 2026 (Last updated: March 27, 2026) BioPharma Dive Some investors and analysts believe the pharma s $6.7 billion offer is justified given Terns recent stock run. M&A / DealsRead full story Post navigation Previous: FDA clears Denali drug in ‘clear step’ for rare disease biotechsNext: The Rare Journey Needs a Special Pharmacy Partner Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026